Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARERE trial of panitumumab rechallenge followed by regorafenib versus the reverse sequence in chemorefractory RAS/BRAF wild-type metastatic colorectal cancer
2024-513296-41-00Phase 2Completed
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab and regorafenib in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Overall survival. Started Sep 2024; status: completed.
02
Drugs
panitumumabregorafenib
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2024-513296-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513296-41-00.